Novartis's US unit to plead guilty in Trileptal off-label probe
This article was originally published in Scrip
Executive Summary
Novartis's US subsidiary is working to resolve a federal probe relating to the marketing of the seizure therapy Trileptal (oxcarbazepine) and several other medicines.